Dr. reddy's laboratories announces approval for lenalidomide capsules from the u.s. food and drug administration (usfda)

Hyderabad, india & princeton, n.j.--(business wire)--dr. reddy's laboratories ltd. (bse: 500124, nse: drreddy, nyse: rdy, nseifsc: drreddy, along with its subsidiaries together referred to as “dr. reddy's”) today announced the final approval of its abbreviated new drug application (anda) for lenalidomide capsules, in 2.5 mg and 20 mg strengths, and tentative approval for 5 mg, 10 mg, 15 mg, and 25 mg strengths, a therapeutic equivalent generic version of revlimid® (lenalidomide) capsules, from
RDY Ratings Summary
RDY Quant Ranking